What dr max pharma does

Dr. Max Pharma s.r.o. is a Czech private-label pharmaceutical manufacturer and product development company headquartered in Prague, founded in 2011 and wholly owned by Penta Investments through the Dr. Max Group. The company develops and supplies an own-brand portfolio of more than 1,340 SKUs across five categories: food supplements (53.8% of portfolio), OTC medicines (15.2%), medical devices (15.9%), cosmetics (6.6%), and prescription pharmaceuticals (5.7%). Distribution is exclusively through the affiliated Dr. Max pharmacy chain, which operates 3,005 pharmacies across six European markets (Czech Republic, Romania, Italy, Poland, Slovakia, Serbia) and accounts for 300,000 units sold daily as of 2024.

The company collaborates with more than 400 global suppliers, primarily in Europe and Asia, and holds proprietary brand identities including BEBELO (baby care, launched 2020), Nuance (luxury cosmetics, launched 2015), PRO32, MaxMobility, and the Medreg generic RX range. Dr. Max Pharma obtained Good Manufacturing Practice (GMP) certification in 2024, establishing compliance with European pharmaceutical manufacturing standards across multi-market product registration and pharmacovigilance systems. The company was ranked No. 1 producer in Czech Republic pharmaceutical retail by IQVIA in 2023.

The business model is a vertically integrated private-label operation: Dr. Max Pharma develops, sources, and supplies own-brand products that are sold exclusively through its sister pharmacy chain under common Penta Investments ownership. Revenue is captured at the wholesale/manufacturing level rather than retail, with no disclosed third-party customers. A merger with sister company Medreg was initiated on May 18, 2026, with an effective date of January 1, 2027, intended to consolidate generic RX operations within the group.

Name

dr max pharma

Legal name

Dr. Max Pharma s.r.o.

Website

https://drmaxpharma.com

Company type

Private

Founded year

2011

Operating status

Operating

Short description

Dr. Max Pharma is a Prague-based private-label pharmaceutical manufacturer, wholly owned by Penta Investments, that develops and supplies over 1,340 own-brand SKUs (supplements, OTC, devices, cosmetics, RX drugs) exclusively to the 3,005-pharmacy Dr. Max chain across six European countries.

Ownership category

akta.pro rank

Product category

Private-label pharmaceutical manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Private label pharmaceuticals
• OTC medicines
• Food supplements
• Medical devices
• Generic prescription drugs

Headquarters

HQ city

Prague

HQ country

Czechia

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Private Label Pharmaceutical Product Sales: Dr. Max Pharma generates revenue by developing and supplying private-label pharmaceutical and health products (OTC medicines, food supplements, medical devices, cosmetics, RX drugs) to the Dr. Max pharmacy chain across six European countries. Products are sold under owned brands including BEBELO (baby care), Nuance (cosmetics), PRO32, and MaxMobility. The company collaborates with over 400 suppliers worldwide to manufacture products that are distributed exclusively through Dr. Max retail pharmacies and e-commerce platforms.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Dr. Max Pharma develops and manufactures private-label pharmaceutical and healthcare products — including food supplements, OTC medicines, medical devices, cosmetics, and RX prescription drugs — under proprietary brands such as BEBELO, Nuance, PRO32, MaxMobility, and Medreg. The company operates as the product development and sourcing arm of the Dr. Max pharmacy chain, distributing exclusively through Dr. Max retail pharmacies and e-commerce platforms across six European countries (Czech Republic, Romania, Italy, Poland, Slovakia, Serbia).

Product overview

Dr. Max Pharma is a pharmaceutical company and private-label product manufacturer for the Dr. Max pharmacy chain, operating as the pioneer of successful private label projects in Central Europe. The company offers a diversified portfolio exceeding 1,340 SKUs across multiple product categories: Food Supplements (53.8%) including vitamins and minerals; OTC medicines (15.2%) like ibuprofen and paracetamol; Medical Devices (15.9%) including nasal sprays and lozenges; Cosmetics (6.6%) including the Nuance luxury brand; and Prescription (RX) pharmaceuticals (5.7%) under the Medreg brand. Specialized sub-brands include BEBELO® for baby care, PRO32, and MaxMobility. The products are sold across six European markets (Czech Republic, Romania, Italy, Poland, Slovakia, Serbia) through Dr. Max pharmacies and other retail channels.

Differentiator

Problem solved

Functional benefit

Brands

• BEBELO: Exclusive brand for the complete care of mothers and babies, including baby and toddler formula, diapers and gentle baby cosmetics.
• Nuance
• PRO32
• MaxMobility
• Medreg

Products and services

• Food Supplements Vitamins, minerals, and dietary supplements that support everyday health and wellness, comprising 53.8% of the product portfolio. Targeted at consumers seeking preventive health, nutritional support, and immune system maintenance.
• OTC (Over-the-Counter Medicines) Non-prescription medications including pain relievers (Ibuprofen, Paracetamol, Diclofenac), respiratory treatments (Acetylcystein, Ambroxol), and allergy relief (Cetirizin), representing 15.2% of the portfolio. Designed for consumers seeking self-medication options for common ailments.
• Medical Devices

Quantifiable outcome

• 300,000 units sold daily
• +3 more outcomes

Named customers7 records

Segments7 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered major and core.

• A&D PharmamajorOthers · 1 January 2019Dr. Max Group completed its largest acquisition in history - the takeover of A&D Pharma in 2019. This acquisition enabled the launch of extensive private label portfolio in Romania, expanding Dr. Max Pharma's market presence significantly in that country.
• MedregcoreStrategic or Co-development Partner · 1 January 2016Strategic partnership with Medreg to expand portfolio to include RX/generic drugs, boosting market strength. First registered products under this partnership include Alergimed (Poland) and Sildenafil Medreg (Slovakia) in 2016. The partnership enabled Dr. Max Pharma to enter the prescription pharmaceutical market.
• Dr. Max GroupcoreOthersDr. Max Pharma is a proud member of the Dr. Max Group, operating as the pharmaceutical manufacturing and private label product development arm. The company supplies own-brand products exclusively to the Dr. Max pharmacy chain across six European countries. The Dr. Max Group includes over 3,000 pharmacies and is a major pharmaceutical retail operator in Central and Eastern Europe.
• Global Pharmaceutical Suppliers (400+)majorOthersDr. Max Pharma collaborates with over 400 suppliers worldwide, particularly in Europe and Asia. Suppliers are carefully selected to ensure quality ingredients and products, with focus on quality, innovation, and sustainability. Long-term, transparent partnerships with suppliers support the company's goal of providing accessible healthcare.

Scale indicators7 records

Recent moves4 records

Expansion highlights5 records

Emerging players

• Apotex: Apotex is one of Canada's largest generic pharmaceutical manufacturers with growing European presence, producing generic RX, OTC, and consumer health products — comparable in private-label generics manufacturing model.
• Dr. Reddy's Laboratories: Dr. Reddy's is a global pharmaceutical manufacturer with growing European OTC and generics presence, particularly through acquisitions — comparable in generic and OTC manufacturing but with a different geographic anchor.

Direct peers

• Perrigo Company: Perrigo is the world's largest manufacturer of private-label over-the-counter and generic pharmaceuticals, supplying retailer-owned brands across Europe and globally — the closest functional analog to Dr. Max Pharma's private-label model for a pharmacy chain.
• Medreich (formerly part of Cipla): Medreich is a contract and private-label pharmaceutical manufacturer supplying OTC and generic products to European retail and pharmacy chains — directly comparable as a private-label contract manufacturer serving pharmacy customers.
• STADA Arzneimittel: STADA is a European-focused generic and consumer healthcare company producing private-label and branded generics, OTC medicines, and food supplements across multiple European markets — directly comparable in geography and product mix.
• Omega Pharma (Perrigo subsidiary): Omega Pharma is a major European OTC and personal care manufacturer owned by Perrigo, producing private-label and brand-equivalent products sold through European pharmacy channels — comparable business model and channel.
• Zentiva Group: Zentiva is a European generic pharmaceutical manufacturer with strong presence in Central and Eastern Europe, producing branded generics, OTC, and consumer health products — overlaps directly with Dr. Max Pharma's CEE-focused portfolio strategy.

Broad incumbents

• Viatris (Mylan + Upjohn): Viatris is a global pharmaceutical company with an extensive generics and OTC portfolio serving European retail pharmacy channels — comparable in product range and channel focus but as a broad incumbent.
• Sandoz Group: Sandoz, spun off from Novartis, is a global leader in generics and biosimilars with significant European manufacturing — comparable in product categories (generics, OTC, specialty pharma) but operates at much larger scale and breadth.
• Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with a broad European portfolio across OTC and RX generics — comparable product categories and scale, but operates as a broad incumbent rather than a private-label specialist.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about dr max pharma